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Remarkably good results have been achieved in the treatment of atherosclerotic cardiovascular diseases
(CVD) by using statin, ezetimibe, antihypertensive, antithrombotic, and PCSK9 inhibitor therapies and
their proper combinations. However, despite this success, the remaining CVD risk is still high. To target
this residual risk and to treat patients who are statin-intolerant or have an exceptionally high CVD risk
for instance due to familial hypercholesterolemia (FH), new therapies are intensively sought. One
pathway of drug development is targeting the circulating triglyceride-rich lipoproteins (TRL) and their
lipolytic remnants, which, according to the current view, confer a major CVD risk. Angiopoietin-like
protein 3 (ANGPTL3) and apolipoprotein C-III (apoC-III) are at present the central molecular targets for
therapies designed to reduce TRL, and there are new drugs emerging that suppress their expression or
inhibit the function of these two key proteins. The medications targeting these components are bio-
logical, either human monoclonal antibodies or antisense oligonucleotides. In this article, we briefly
review the mechanisms of action of ANGPTL3 and apoC-III, the reasons why they have been considered
promising targets of novel therapies for CVD, as well as the current status and the most important results
of their clinical trials.
© 2018 Elsevier B.V. All rights reserved.1. Introduction
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lkkonen).concomitant chronic inflammation of the arterial wall [1]. In
addition to LDL-C and other established conventional risk factors,
the role of TRL as a causal CVD risk factor is increasingly recognized
[2]. Variants of a number of key genes of TRL metabolism display
strong associations with CVD risk, and the strength of these vari-
ants' impacts on plasma TG concentration correlates with the
magnitude of their effects on the risk of CVD events [3]. TRLs are
envisioned to contribute to the progression of CVD via multiple
mechanisms: They directly mediate cholesterol deposition within
the arterial intima and facilitate the activation of pro-inflammatory,
pro-coagulant, and pro-apoptotic pathways [4]. Chylomicron and
VLDL remnants have average diameters <70 nm and therefore
penetrate into the arterial intima, and are there retained by the
connective tissue matrix [5,6]. Besides TGs, these remnant particles
also contain enriched amounts of cholesterol esters and can be
taken up by arterial macrophages resulting in elevated cholesterol
loading and accelerated foam cell formation in coronary arteries
[7]. The crucial importance of TRL and their lipolytic remnants in
CVD progression is supported by the fact that non-HDL cholesterol
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containing particles: LDL, TRL, Lp(a) and TRL remnants, provides a
better prediction of CVD risk than LDL-C [8]. Despite the statin,
ezetimibe, antihypertensive and antithrombotic therapies
routinely used to treat atherosclerotic CVD, as well as the PCSK9
antibody therapy which is currently being devised, these diseases
are still the leading cause of death in the industrialized societies,
and their role is constantly increasing also in the developingmarket
economies [9]. Much of the progress in treating CVD with associ-
ated dyslipidemia can be attributed to the development and
application of therapeutic approaches that reduce plasma low-
density- lipoprotein cholesterol (LDL-C). However, even when
applying aggressive LDL-C reducing tools, a significant residual risk
remains, and during the last years the decline in CVD deaths has
reached a plateau [10]. The current epidemic increase in obesity,
metabolic syndrome and type 2 diabetes (T2D), which are associ-
ated with so called atherogenic dyslipidemia characterized by
elevated plasma triglyceride (TG) and TRL levels, low HDL-C, and
frequently with small dense LDL and small-sized HDL particles,
critically contributes to the observed halt of the progress in risk
reduction [11,12]. An intensive search for new molecular targets of
CVD therapy is therefore ongoing. In addition, newmedications are
particularly important considering the treatment of patients with
familial hypercholesterolemia (especially homozygous FH patients,
HoFH), since the efficacy of both statin and PCSK9 inhibitor thera-
pies largely depends on functional LDL receptors. Therefore, the
functionality of the above widely used medications is poor in pa-
tients with FH mutations affecting the LDL receptor [3]. Several of
the new CVD therapy targets impact the quality and/or concen-
tration of serum lipoproteins that transport cholesterol and TG:
Angiopoietin-like protein 3, ANGPTL3 [13], apolipoprotein C-III,
apoC-III [14], cholesterol ester transfer protein, CETP [15], and li-
poprotein (a), Lp(a) [16] all affect specific processes within
cholesterol or TG metabolism. Of these, ANGPTL3 and apoC-III
represent central regulators of TG and TRL metabolism. In the
present article we briefly review the reasons why functional inhi-
bition of these two molecular targets with specific effects on TLR
and their metabolism has been anticipated to be beneficial and
what we have thus far learned from their clinical trials.
2. ANGPTL3 as a therapy target
ANGPTL3 belongs to the ANGPTL-protein family comprising 8
members (ANGPTL1-8) and is composed of an N-terminal coiled-
coil domain and a fibrinogen-like C-terminal domain [13,17].
ANGPTL3 is almost exclusively synthesized in the liver, acts in
concert with the related protein ANGPTL8 [18,19], and inhibits the
activity of LPL and thus the hydrolysis of TGs in capillaries of adi-
pose tissue and muscles (Fig. 1). Apart from inhibiting LPL,
ANGPTL3 can also inhibit endothelial lipase (EL) activity and
thereby affect serum HDL-C levels [20]. ANGPTL3 expression in the
liver of diabetic mice and in cultured human hepatocytes is
dampened by insulin, suggesting that its down-regulation allows
upon feeding a high LPL activity in extrahepatic tissues in order to
facilitate efficient fatty acid release from TG and uptake by tissues
for energy production or storage [21,22]. Progress in elucidating the
role of ANGPTL3 in human lipid metabolism has been made
through the identification of individuals carrying inactivating mu-
tations in the ANGPTL3 gene [23]. Genetic loss-of-function (LOF) of
ANGPTL3 causes familial combined hypolipidemia (FHBL2,
OMIM#605019) characterized by very low plasma TG, LDL-C and
HDL-C concentrations. Particularly interesting is the ANGPTL3 S17X
mutation detected in three generations in the small town of Cam-
podimele in Italy [24,25]. This town has drawn the attention of
researchers and was chosen as a site of WHO's CVD research in the1990s. The life expectancy of both females and males in Campo-
dimele is 95 years, which is approximately 20 years more than
elsewhere in Italy. The inbred inheritance of ANGPTL3 LOF muta-
tions is considered one of the central factors underlying this
longevity. Homozygous carriers of the S17X mutation had signifi-
cantly higher LPL activity and mass in post-heparin plasma than
non-carriers. Moreover, plasma free fatty acids, insulin, glucose,
and homeostatic model assessment of insulin resistance (HOMA-
IR) were significantly lower in homozygous S17X subjects than in
heterozygotes or non-carriers. Complete ANGPTL3 deficiency was
also associated with significantly blunted postprandial lipemia af-
ter high fat, high calory-containing meal. Since the discovery of the
ANGPTL3 S17X mutation, several additional LOF mutations have
been identified in ANGPTL3, including G400VfsX5, I19LfsX22,
N147X,N121LfsX3, N121fsX9, R332Q, S122KfsX3, E119fsX8, G56V,
F295L, E96del, E95del [25e27]. When these variants exist in a
homozygous or compound heterozygous state, they all lead to
FHBL2. To conclude, ANGPTL3 seems to play important roles in both
lipid and glucose metabolism [28,29]. The mechanism of LDL
reduction upon loss of ANGPTL3 function was earlier not known;
however, using a human hepatocyte model with CRISPR-Cas9
mediated knock-out of ANGTPL3 evidence was presented that the
LDL reduction results from a combination of attenuated hepatic
apoB-100 secretion and increased uptake of apoB-100 containing
lipoproteins. The increased hepatic particle uptake was apparently
a result of elevated LDL receptor and LRP-1 expression [30].
Consistent with an intracellular function of ANGPTL3 in hepatic
lipid metabolism, knockdown of ANGPTL3 in cultured human he-
patocytes reduced the lipidation of VLDL upon insulin stimulation
and induced distinct changes in the expression of genes regulating
lipid metabolism [31]. Meta-analysis of 19 studies (a total of 21,980
CVD patients and 158,200 controls) demonstrated that carriers of
ANGPTL3 LOF mutations have 34% lower CVD risk than the control
individuals [32]. Subjects in the lowest tertile of ANGPTL3 con-
centration displayed 29% lower myocardial infarction (MI) risk than
the highest tertile. Consistently, a reduction of CVD risk in ANGPTL3
LOF mutation carriers was replicated when the exons of ANGPTL3
were sequenced among 58,335 participants of the DiscovEHR hu-
man genetics study [33]. Participants with heterozygous LOF vari-
ants in ANGPTL3 had significantly lower serum TG, HDL-C and LDL-
C concentrations than participants lacking these variants. Associa-
tion of ANGPTL3 LOF variants with coronary artery disease (CAD) in
13,102 CAD patients and 40,430 controls from the DiscoEHR study
showed that the LOF variants were found in 0.33% of the cases and
in 0.45% of the controls (adjusted odds ratio, 0.59; 95% confidence
interval, 0.41 to 0.85; p¼ 0.004). These results were further
confirmed in follow-up studies from four large population cohorts,
showing that genetic antagonism of ANGPTL3 in humans is asso-
ciated with decreased levels of all three major lipid fractions (VLDL,
LDL, HDL) and a decreased risk of atherosclerotic CVD. The above
epidemiological and preclinical studies suggest that the plasma TG
lowering facilitated by reduced ANGPTL3 outweighs the potential
negative consequences associated with the HDL-C lowering. Clin-
ical trials on the inhibition of ANGPTL3 are ongoing at phases I and
II. The therapeutic agents in these studies are antisense oligonu-
cleotides (ASO, IONIS-ANGPTL3-LRx), which dampen hepatic
ANGPTL3 expression by targeting its mRNA, or a human mono-
clonal antibody against ANGPTL3 (Evinacumab). Both the ASO and
antibody therapies significantly reduced the plasma concentrations
of serum ANGPTL3 and all major lipoprotein classes. After 6 weeks
of treatment, subjects who received ASO had reduced levels of
ANGPTL3 protein (reductions of 46.6e84.5% from baseline, p< 0.01
for all doses vs. placebo) and of triglycerides (reductions of
33.2e63.1%), LDL cholesterol (1.3e32.9%), VLDL-C (27.9e60.0%),
non-HDL-C (10.0e36.6%), apoB (3.4e25.7%), and apoC-III
Fig. 1. The functions of angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C-III (apoC-III) in lipoprotein metabolism and their impacts on atherogenesis. The dashed blue
lines depict the inhibition of LPL activity, the hepatic uptake of VLDL and chylomicron remnants or LDLR/LRP-1 expression, and the red arrows the resulting accumulation of
atherogenic lipoproteins in atherosclerotic plaques within the arterial wall. The suggested intrahepatocellular functions of ANGPTL3 and apoC-III as facilitators of VLDL assembly
and secretion are indicated with a green arrow. The role of apoC-III in intestinal TRL metabolism is thus far unknown. CM, chylomicron; HL, hepatic lipase; LDL, low-density-
lipoprotein; LDLR, LDL receptor; LPL, lipoprotein lipase; LRP-1, LDL receptor-related protein 1; R, remnant; VLDL, very-low-density-lipoprotein. (For interpretation of the refer-
ences to colour in this figure legend, the reader is referred to the Web version of this article.)
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caused a dose-dependent placebo-adjusted reduction in fasting TG
of up to 76% and LDL-C of up to 23%. Since the results of these
clinical trials are very promising, the study of the ANGPTL3 in-
hibitors will most likely progress into phase III. In addition, it is
noteworthy that Evinacumab administered on top of intense statin
therapy for 4 weeks resulted in a further reduction of LDL-C (by
50%), TG (by 47%) and HDL-C (by 36%) in a group of 9 homozygotic
FH patients, suggesting that ANGPTL3 inhibition could be employed
as a strategy to reduce the high residual risk apparent in subjects
with FH [35]. While Evinacumab antibody therapy mainly targets
the ANGPTL3 protein in the circulation, ASO targets the synthesis of
ANGPTL3 in hepatocytes and thus also its putative intracellular
functions [30,31]. Therefore, these two types of biological drugs
could, despite similar effects on plasma TG and lipoproteins, differ
in their effects on liver physiology. This prompts further, detailed
research of the intrahepatocellular functions of ANGPTL3.
3. Inhibition of apoC-III as a therapeutic strategy
Apolipoprotein C-III is a small, 79-amino acid glycosylated
protein expressed by hepatocytes and enterocytes. It is primarily acomponent of the TRL, but also, to a lesser extent, detectable in LDL
and HDL. The classic function of apoC-III is the inhibition of LPL and
hepatic lipase, resulting in marked effects on the concentrations of
circulating TRL [36,37] (Fig. 1). Additionally, apoC-III is shown to
facilitate the synthesis and secretion of VLDL by hepatocytes [38].
Consistently, two naturally occurring point mutations in APOC3,
A23T and K58E, have been shown to abolish the intracellular as-
sembly and secretion of large TG-rich VLDL1 particles from the liver
[39,40]. Furthermore, apoC-III is shown to enhance the atheroge-
nicity of LDL by increasing its affinity for arterial wall proteoglycans
[41], to confer proatherogenic properties to HDL [42], as well as to
promote the activation of endothelial cells and monocyte adhesion
[43,44]. Importantly, apoC-III also interferes with the binding of
apoB or apoE to hepatic LDL-receptor (LDLR) and LRP-1, thus
resulting in a delayed catabolism of the highly atherogenic VLDL
and chylomicron remnants [45,46]. Of note, the study of Gaudet
et al. [47] on patients with familial chylomicronemia syndrome,
characterized by the lack of LPL activity, showed a significant
reduction of TGs upon apoC-III ASO treatment, consistent with an
important, LPL-independent function of apoC-III. This effect was
recently explained by a murine model study demonstrating that
apoC-III ASO treatment failed to lower TGs in mice lacking both
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apoC-III in lipoprotein clearance seems to be a key factor underly-
ing its impact on plasma TG levels. Epidemiologic studies have
shown that the concentration of apoC-III in plasma, VLDL, and LDL
predicts CVD [49e51], and a 15-year prospective study demon-
strated that it also predicts mortality [52]. Moreover, apoC-III levels
in patients with T2Dwere found to associatewith increased plasma
TGs and elevated coronary artery calcification [53]. Genome-wide
association studies (GWAS) revealed an association of plasma TG
concentrations and risk of CVD with the apoA-V/A-IV/C-III/A-I gene
cluster [54]. This association is now believed to reflect a causal role
of apoC-III in regulating the concentration of plasma TG, revealed
upon the discovery of LOF variants in the APOC3 gene. Consistently,
LOF variants that inactivate apoC-III not only reduce the serum TG
concentration but also protect from CAD [55e57], and a recent
meta-analysis of published studies confirmed a positive association
of plasma apoC-III and CVD [58].
Previously, homozygous APOC3 LOF varient carriers were not
found despite the fact that approximately 200,000 US and Euro-
pean subjects have been studied, possibly suggesting that a com-
plete deficiency of apoC-III could be harmful. However, this seems
not to be the case since four subjects homozygous for an APOC3 LOF
variant (p.Arg19Ter) were recently discovered [59]. Compared with
non-carriers, p. Arg19Ter homozygote subjects presented with an
extremely low plasma apoC-III concentration (89%, p¼ 5 10e23),
reduced TG concentration (60%, p ¼ 7  104), elevated HDL-C
(þ0.69 mmol/L, p¼ 3 108) and very similar LDL-C levels. Inter-
estingly, when these human APOC3 deficient subjects were chal-
lenged with an oral fat load they displayed a markedly blunted
post-prandial response in plasma TG as compared with control
family members. Due to these observations, apoC-III has evoked
marked interest as a target of CVD drug development.
Statins have been reported to moderately reduce plasma apoC-
III concentration [60,61]. Moreover, there is evidence from both
animal and human studies that peroxisome proliferator receptor a
(PPARa) agonists (fibrates) reduce the hepatic expression of apoC-
III and its concentration in plasma [62]. However, there is no data
available on a putative connection of the CVD outcomes in clinical
trials of fibrateswith the fibrate effects on circulating apoC-III levels
[14]. Themajor strategy for inactivation of apoC-III is dampening its
expression with ASO (Volanesorsen¼ IONIS-APOCIIIRx). In phase I
trials the ASO robustly reduced the plasma apoC-III and TG levels in
multiple animal models and in human volunteers [63]. In phase II
clinical trials, Volanesorsen reduced serum apoC-III in a dose-
dependent manner by 40e80%, TG by 31e71%, and elevated HDL-
C by 37e46% without significant side effects [47,63,64]. Impor-
tantly, the ASO treatment also strongly reduced the highly
atherogenic TRL remnants [64]. At the moment, there are three
phase III clinical trials ongoing in subjects with various forms of
severe hypertriglyceridemia: APPROACH on patients with familial
chylomicronemia (https://clinicaltrials.gov/ct2/show/
NCT02211209), COMPASS on hyper-TG patients (https://
clinicaltrials.gov/ct2/show/NCT02300233), and BROADEN on pa-
tients with familial partial lipodystrophy (https://clinicaltrials.gov/
ct2/show/NCT02527343) [65]. These studies will allow us to eval-
uate the efficacy of apoC-III inhibition in reducing CVD events in
extreme hyper-TG cases, hopefully paving the way for apoC-III-
targeting therapies to reduce the residual risk also in other
groups of patients.
4. Conclusion
To reduce the residual risk remaining after conventional CVD
therapies, it is necessary to find new drug modalities. Furthermore,
the efficacy of statins and PCSK9 inhibitors is largely based on LDLreceptor function. Therefore, these therapies typically have a poor
efficacy in carriers of FHmutations, and new treatment regimes are
needed. The current epidemic of obesity, metabolic syndrome and
T2D frequently results in a dyslipidemia characterized by elevated
levels of TRLs and their remnants, which form a major source of
CVD risk. Of the new biological medications that specifically affect
the metabolism of TRLs, the most promising are those targeting
ANGPTL3 and apoC-III. Phase III trials are currently underway with
an apoC-III ASO (IONIS-APOCIIIRx¼ Volanesorsen). The biological
ANGPTL3 inhibitors (IONIS-ANGPTL3-LRx and Evinacumab) are
subject to great expectations, and will most likely soon proceed to
phase III trials. As the choice of available medications will in the
future expand, the treatment of atherosclerotic CVD will become
more complex. On top of statin therapy, which forms the basis of
the therapeutic regimes for atherosclerotic CVD, additional treat-
ments will be tailored individually for each patient. Targeting the
metabolism of TLR with the presently developed biological drugs
will most likely constitute a fundamental tool in overcoming the
residual CVD risk remaining after conventional therapies, as well
the risk in specific groups of subjects with whom satisfactory re-
sults are not achieved with the present therapeutic approaches.
Although human genetics has identified a number of novel genes
with key roles in lipid metabolism, which can be specifically tar-
geted to attenuate the risk for CVD, drugs targeting these genes/
mRNAs or their protein end-products typically require frequent
administration through injections for decades to facilitate maximal
benefit. Thus, albeit the new TRL-targeting biological medications
hold a lot of promise, the administration methods, combined with
the high financial cost of the medications, will limit their use. The
recently introduced genome editing technologies, such as CRISPR-
Cas9, have the advantage of permanently modifying genes and
may thereby enable long-term, even lifelong protection against
atherosclerotic CVD. Even though a number of challenging tech-
nical problems need to be solved before this technology can be
safely applied to cardiovascular medicine [66], we believe that the
genome editing approaches will in the long run emerge as major
therapeutic strategies.
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